Lushang Freda Pharmaceutical Co.,Ltd. (Stock Code: 600223) is a state-controlled listed company focused on pharmaceuticals and cosmetics. Integrating R&D, production, and trade within an industrial-academic-research ecosystem, it operates across cosmetics, pharmaceuticals, active pharmaceutical ingredients (APIs), medical devices, health supplements, and functional foods. As the founder and leader of China's hyaluronic acid industry, the company has been recognized as a "Top Ten Industrial Leader" in Shandong Province and ranked among China's Top 10 Listed Companies in the Beauty Sector
The company steadfastly pursues innovation-driven development, guided by market demand and driven by product innovation. With a 400-member R&D team operating through 4 national-level platforms (including the National Enterprise Technology Center and Academician Workstation) and 17 provincial R&D facilities, it forges sustained industry-academia-research synergies with leading institutions such as Zhejiang University, Shandong University, and Shanghai Institute of Materia Medica under Chinese Academy of Sciences. This ecosystem has enabled the completion of over 30 national/ministerial R&D projects, secured 400+ patents, and earned 3 Second Prizes plus 1 Third Prize in China's National Science and Technology Progress Awards – culminating in its designation as a National Technology Innovation Demonstration Enterprise

Embodying its commitment to sustainable development, the company accelerates technology-driven industrialization with seven specialized production bases in Jinan, Linyi, Jining, and Yili (Xinjiang) – manufacturing synthetic biological materials, botanical extracts, chemical intermediates, pharmaceutical formulations, and skincare/fragrance cosmetics. This ecosystem includes 2 National Green Factories and 1 Provincial Smart Facility. Operating a quality management system aligned with ICH, FDA, EDQM (EU), and PMDA (Japan) standards, its pharmaceutical production holds current GMP certification while cosmetics labs maintain CNAS accreditation. Leveraging uncompromising product quality and customer-centric service, the corporation has established the "Freda" master brand in healthcare, with iconic sub-brands including "Yilian" (Lotus Care), "Aier Boshi" (Dr. Alva), "Yipaerhan" (Ile Fragrance), "Mingren", "Runjie", and "Special". Products now reach over 70 countries across North America, EU, Japan-Korea, and Southeast Asia
Moving forward, Freda will uphold its mission of "Creating a Healthy Ecosystem through Science and Technology", accelerating value reinvention across strategy, operations, organization, and culture. The company implements its "1234" High-Quality Innovation Strategy: consolidating leadership in hyaluronic acid technology while focusing on dual core businesses – specializing and scaling the pharmaceutical division, strengthening and upgrading the cosmetics segment. This drives triple transformation along differentiated, ecosystem-based, and internationalized development pathways, powered by four strategic engines: R&D driving, talent attraction, brand leveraging, and digital-intelligence enablement. Ultimately, Freda strives to become a globally trusted leader in pharmaceutical and wellness innovation